The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now. Royalty Pharma Plc (NASDAQ:RPRX) announced on April 17 that its board of directors approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. Management stated that the dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. In a separate development, Morgan Stanley lifted the price target on Royalty Pharma Plc (NASDAQ:RPRX) to $63 from $61 on April 10, reiterating an Overweight rating on the shares and adjusting models among the stocks under its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of the group’s fiscal Q1 earnings reports.

Royalty Pharma Plc (NASDAQ:RPRX) also announced on March 30 a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027, aimed at advancing the development of JNJ-4804, an investigational medicine for autoimmune diseases.

Royalty Pharma Plc (NASDAQ:RPRX) funds innovation in the biopharmaceutical industry and buys biopharmaceutical royalties. It collaborates with innovators from research hospitals, non-profits, and academic institutions through small and mid-cap biotech companies to global pharma companies. The company funds innovation in the industry both directly, by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly, by acquiring existing royalties from the original innovators.

While we acknowledge the potential of RPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.